AZD8931

DRUG10 trials

Sponsors

AstraZeneca, University College, London, UNICANCER

Conditions

Advanced Solid MalignanciesBreast CancerBreast NeoplasmsHealthyMetastatic Breast CancerMetastatic CancerMetastatic Colorectal CancerMetastatic, Gastric or Gastro-oesophageal Junction, Cancer

Phase 1

Study of AZD8931 in Patients With Advanced Solid Malignancies

CompletedNCT00637039

AstraZenecaAdvanced Solid Malignancies

Start: 2008-02-29End: 2012-12-31Updated: 2013-03-12

A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets

CompletedNCT00879346

AstraZenecaHealthy

Start: 2009-03-31End: 2009-07-31Target: 24Updated: 2009-10-23

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

CompletedNCT00900627

AstraZenecaBreast Cancer, Breast Neoplasms, Neoplasms

Start: 2009-06-30End: 2015-02-28Updated: 2016-01-20

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.

CompletedNCT01003158

AstraZenecaBreast Cancer, Metastatic Cancer, Neoplasms

Start: 2009-10-31End: 2012-04-30Updated: 2014-07-10

A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females

CompletedNCT01330758

AstraZenecaHealthy

Start: 2011-04-30End: 2011-05-31Target: 26Updated: 2011-07-29

Phase 2

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

TerminatedNCT01151215

AstraZenecaBreast Cancer, Breast Neoplasms, Neoplasms

Start: 2010-06-30End: 2013-01-31Updated: 2014-07-25

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

TerminatedNCT01579578

AstraZenecaMetastatic, Gastric or Gastro-oesophageal Junction, Cancer

Start: 2012-04-30End: 2013-03-31Updated: 2014-09-12

Phase I/II Trial of Antagonism of HER in GI Cancer

CompletedNCT01862003

University College, LondonMetastatic Colorectal Cancer, Recurrent Colorectal Cancer

Start: 2014-05-31End: 2019-08-02Updated: 2019-08-19

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

CompletedNCT02117167

UNICANCERNon-small Cell Lung Cancer Metastatic

Start: 2014-04-23End: 2023-12-31Updated: 2024-01-10

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruitingNCT02299999

UNICANCERMetastatic Breast Cancer

Start: 2014-04-07End: 2025-12-31Updated: 2025-01-15

Related Papers

Mapping the rapid growth of multi-omics in tumor immunotherapy: Bibliometric evidence of technology convergence and paradigm shifts

Human Vaccines & Immunotherapeutics2025-04-243 citations

Genomic instability in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/ IFCT1301 trial.

Journal of Clinical Oncology2024-06-011 citations

251P Genomic alterations of breast cancer patients with leptomeningeal disease: A retrospective analysis

ESMO Open2024-05-011 citations

Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.

Journal of Clinical Oncology2023-06-011 citations

PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.

2022-11-0911 citations

Genomics to select treatment for patients with metastatic breast cancer.

2022-09-07119 citations

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Genome Medicine2021-05-1853 citations

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.

2020-01-24221 citations

Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation

Cancer Research2019-07-012 citations

Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation

Clinical Research (Excluding Clinical Trials)2019-07-01

An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.

Journal of Clinical Oncology2018-05-205 citations

Treatment for Metastatic HER2 Breast Cancer Patients With High Loss of Heterozygosity

Oncology Times2017-08-04

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.

2016-11-0115 citations

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.

2016-09-2128 citations

Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.

2014-05-318 citations

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.

2013-04-1621 citations